Effect of adding liraglutide vs placebo to a high-dose lnsulin regimen in patients with type 2 diabetes a randomized clinical trial

Medicine & Life Sciences

• Liraglutide 100%
• Type 2 Diabetes Mellitus 53%
• Placebos 49%
• Insulin 48%
• Randomized Controlled Trials 48%
• Hypoglycemia 27%
• Glycated Hemoglobin A 22%
• Therapeutics 11%
• Glucagon-Like Peptide-1 Receptor 9%
• Weights and Measures 9%
• Subcutaneous Injections 7%
• Weight Gain 6%
• Risk Assessment 5%
• Body Weight 5%
• Quality of Life 4%
• Safety 4%
• Population 2%